Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFEGUARD FP
2016-002271-97Phase 2Completed
- Sponsor
- F2G
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olorofim in invasive mycoses and mycoses (2 arms), sponsored by F2G. Primary endpoint: Safety and tolerability. Started Jan 2017; status: completed.
02
Drugs
olorofim
03
Conditions
invasive mycosesmycoses
Beyond the preview
Go deeper on 2016-002271-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002271-97.